TA 0201

Drug Profile

TA 0201

Alternative Names: T 0201

Latest Information Update: 08 Aug 2002

Price : $50

At a glance

  • Originator Tanabe Seiyaku
  • Class Anti-ischaemics; Heart failure therapies
  • Mechanism of Action Endothelin A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Heart failure; Pulmonary hypertension; Reperfusion injury

Most Recent Events

  • 09 Nov 1999 A preclinical study has been added to the Vascular Disorders pharmacodynamics section
  • 25 Sep 1998 Preclinical development for Pulmonary hypertension in Japan (Unknown route)
  • 25 Sep 1998 Preclinical development for Reperfusion injury in Japan (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top